Part A:Placebo
Sponsors
Shanghai General Hospital, AstraZeneca
Conditions
Dyslipidemiaautoimmune diseases
Phase 1
A Study of AZD8233 in Participants With Dyslipidemia.
CompletedNCT04823611
Start: 2021-01-20End: 2022-09-10Updated: 2024-12-24
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Ascending Doses of ZG-002 Tablets and Food Effect in Healthy Subjects
RecruitingChiCTR2500104658
Start: 2024-10-22Updated: 2025-06-24